Loading
Loading
Research Overview
Oral non-peptide ghrelin mimetic (GHS-R1a agonist); stimulates pulsatile GH release from pituitary somatotrophs and downstream IGF-1 production via the same receptor pathway as endogenous ghrelin, without injection. Appetite stimulation is a direct co-consequence of GHS-R1a activation.
MK-677 (ibutamoren) is an oral ghrelin mimetic that activates ghrelin receptors (GHS-R1a) to stimulate pulsatile growth hormone release and downstream IGF-1 production. Unlike injectable GHRH analogues and GHRPs, its oral bioavailability and approximately 24-hour half-life enable once-daily dosing, which has made it a subject of research interest for prolonged GH-axis modulation studies.
Research using MK-677 has explored its effects on body composition, sleep architecture, nitrogen balance, and bone mineral density. Clinical studies have generally used doses between 10–25 mg daily, with IGF-1 and GH pulse metrics used as primary pharmacodynamic endpoints.
The compound's appetite-stimulating properties stem from the same ghrelin-receptor pathway that drives GH release — ghrelin is the endogenous 'hunger hormone', so GHS-R1a activation inevitably engages appetite centres alongside somatotroph stimulation. This dual effect is a consistent finding across MK-677 research contexts.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, mk-677 (ibutamoren) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
MK-677 (Ibutamoren) research is most relevant to protocols examining:
GH secretagogue research without injections (oral bioavailability)
IGF-1 elevation and body composition studies
Sleep quality and slow-wave sleep investigations
Researchers comparing oral vs injectable GH-secretagogue mechanisms
Initial phase
Effects begin quickly. Initial signalling starts within the first few days. Start at the lowest dose and assess tolerance.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~24 hours). Review data, confirm baseline recovery before any repeat protocol.
Oral non-peptide ghrelin mimetic (GHS-R1a agonist); stimulates pulsatile GH release from pituitary somatotrophs and downstream IGF-1 production via the same receptor pathway as endogenous ghrelin, without injection. Appetite stimulation is a direct co-consequence of GHS-R1a activation.
| Parameter | Value |
|---|---|
| Dose range | 10–25 mg/day |
| Schedule | Once daily (before bed) |
| Route | Oral |
| Half-life | ~24 hours |
can be substantial)
Community & Anecdotal Signal
Community signal is high-volume and more mixed than any Growth Hormone compound. Ibutamoren's oral bioavailability and low cost make it widely used, producing a large and diverse anecdotal pool. Sleep quality improvements are the most consistently reported benefit, often described as dramatic within days of starting. Hunger increase is almost universally reported and is the most common reason for discontinuation. Water retention and mild edema are frequent early side effects. Long-term use reports raise questions about insulin sensitivity and blood glucose, a concern the more sophisticated com
Anecdotal reports are not clinical evidence. Signal may reflect sourcing quality, dosing variation, and expectation bias.
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.